A Phase Ib/II Study of Anti-CD30 Chimeric Antigen Receptor T Cells for Relapsed/Refractory CD30+ Lymphomas
Sign Up to like & getrecommendations! Published in 2019 at "Biology of Blood and Marrow Transplantation"
DOI: 10.1016/j.bbmt.2018.12.149
Abstract: Introduction Treatment with chimeric antigen receptor modified T cells targeting CD30 (CD30.CAR-Ts) without lymphodepletion was found to be safe with preliminary efficacy in patients (pts) with relapsed/refractory (r/r) CD30+ lymphomas (Ramos et al., JCI 2017).… read more here.
Keywords: benda; flu; lymphodepletion; cd30 ... See more keywords
Bendamustine is a safe and effective lymphodepletion agent for axicabtagene ciloleucel in patients with refractory or relapsed large B-cell lymphoma
Sign Up to like & getrecommendations! Published in 2024 at "Journal for Immunotherapy of Cancer"
DOI: 10.1136/jitc-2024-008975
Abstract: Background Fludarabine in combination with cyclophosphamide (FC) is the standard lymphodepletion regimen for CAR T-cell therapy (CAR T). A national fludarabine shortage in 2022 necessitated the exploration of alternative regimens with many centers employing single-agent… read more here.
Keywords: lymphodepletion; cell lymphoma; bendamustine; axicabtagene ciloleucel ... See more keywords
The response to lymphodepletion impacts PFS in patients with aggressive non-Hodgkin lymphoma treated with CD19 CAR T cells.
Sign Up to like & getrecommendations! Published in 2019 at "Blood"
DOI: 10.1182/blood-2018-11-887067
Abstract: Factors associated with durable remission after CD19 chimeric antigen receptor (CAR)-modified T-cell immunotherapy for aggressive B-cell non-Hodgkin lymphoma (NHL) have not been identified. We report multivariable analyses of factors affecting response and progression-free survival (PFS)… read more here.
Keywords: patients aggressive; response; pfs patients; favorable cytokine ... See more keywords
Autologous tumor-infiltrating lymphocytes (HS-IT101) with low-dose lymphodepletion and IL-2 infusion for the treatment of advanced solid tumors: A phase I clinical trial.
Sign Up to like & getrecommendations! Published in 2025 at "Journal of Clinical Oncology"
DOI: 10.1200/jco.2025.43.16_suppl.tps2674
Abstract: TPS2674 Background: Adoptive cell therapy with tumor-infiltrating lymphocytes (TIL-ACT) has demonstrated great therapeutic potential in numerous solid tumors and has become an effective treatment for melanoma. However, high-dose lymphodepletion chemotherapy and IL-2 infusion during the… read more here.
Keywords: lymphodepletion; treatment; clinical trial; dose lymphodepletion ... See more keywords